According to our recent payer coverage analysis for endometriosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access forendometriosis treatments shows that under the pharmacy benefit, about 53% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In April 2020, Myovant Sciences reported positive results in its Phase III studies of once-daily relugolix combination therapy for pain associated with endometriosis.